What's new? Log in Free sign up

Zymeworks (ZYME)

Company Profile

Company profile

Ticker

ZYME

Exchange

Website

www.zymeworks.com

CEO

Mr. Kenneth H. Galbraith C.A.

Incorporated

British Columbia, Canada

Location

British Columbia, Canada

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Mississippi Power • Alabama Power • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris ...

Former names

Zymeworks Inc, Zymeworks Inc.

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Zymeworks Biopharmaceuticals Inc. ...

ZYME stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$19.00

Low target

$14.00

High target

$25.00

Leerink Partners

Upgraded

Outperform

$25.00

7 Nov 24

Latest filings (excl ownership)

View all

Securities registration termination

Entry into a Material Definitive Agreement

Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody

Amendments to Articles of Incorporation or Bylaws

Registration of securities for employees (post-effective amendment)

Registration of securities for employees (post-effective amendment)

Registration of securities for employees (post-effective amendment)

Registration of securities for employees (post-effective amendment)

Automatic shelf registration (post-effective amendment)

Exchange delisting

Transcripts

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

BANK OF AMERICA CORP /DE/

WELLINGTON MANAGEMENT GROUP LLP

Redmile Group, LLC

Paul Andrew Moore

Paul Andrew Moore

All Blue Falcons FZE

All Blue Falcons FZE

Financial summary

Financial statements Chart ZYME financial data

Quarter (USD)	Jun 22	Mar 22	Dec 21	Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	198.65 mm	198.65 mm	198.65 mm	198.65 mm	198.65 mm	198.65 mm
Cash burn (monthly)	25.62 mm	4.88 mm	21.94 mm	20.03 mm	18.27 mm	17.63 mm
Cash used (since last report)	801.28 mm	152.48 mm	686.16 mm	626.33 mm	571.50 mm	551.27 mm
Cash remaining	-602.63 mm	46.17 mm	-487.51 mm	-427.68 mm	-372.85 mm	-352.62 mm
Runway (months of cash)	-23.5	9.5	-22.2	-21.4	-20.4	-20.0

Beta Read what these cash burn values mean

Financial data from Zymeworks earnings reports.

Institutional ownership, Q3 2023

ZYME institutional ownership history Ownership history

16.6% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	3	3	–
Opened positions	0	0
Closed positions	0	0
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	74.38 mm	74.38 mm	–
Total shares	11.41 mm	11.41 mm	–
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Biotechnology Value Fund L P	5.87 mm	$51.60 mm	0.0%
All Blue Falcons FZE	3.99 mm	$0.00	0.0%
Fonds De Solidarite Des Travailleurs Du Quebec	1.55 mm	$22.78 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
Fonds De Solidarite Des Travailleurs Du Quebec	1.55 mm	0.00	0.0%
Biotechnology Value Fund L P	5.87 mm	0.00	0.0%
All Blue Falcons FZE	3.99 mm	0.00	0.0%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Zymeworks Expects $324M Cash Resources, Plus $25M Milestone, To Fund Operations Into 2H-2027

Updated Cash Runway GuidanceAs of December 31, 2024, the Company had cash resources of approximately $324 million (unaudited), consisting of cash, cash equivalents, and marketable securities, not including a $25 million

Deep Dive Into Zymeworks Stock: Analyst Perspectives (10 Ratings)

Wells Fargo Maintains Equal-Weight on Zymeworks, Raises Price Target to $14

JP Morgan Upgrades Zymeworks to Overweight, Announces $18 Price Target

Press releases

From Benzinga Pro

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the

Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026

Investigational new drug (IND) applications for initiating first-in-human studies for ZW220 and ZW251 in solid tumors anticipated in 2025IND applications for initiating first-in-human studies for ZW209 and ZW1528

Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases

Company on track to deliver five Investigational New Drug (IND) applications as part of ‘5 by 5' solid tumor strategy 18 months ahead of original targetNomination of ZW209, a novel trispecific T cell engager, as fifth

Zymeworks Announces Participation in Upcoming Investor Conferences

FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.